非甾体抗炎药：皇帝的新教条？
NSAIDs: the emperor's new dogma?
作者信息
Bjarnason I, Takeuchi K, Simpson R
机构信息
Department of Medicine, Guy's, King's, St Thomas' School of Medicine, London, UK.
出版信息
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
Abstract
The spectacular marketing success of the selective cyclooxygenase 2 (COX-2) inhibitors is largely based on efficacy comparable with conventional non-steroidal anti-inflammatory drugs (NSAIDs) with vastly improved gastrointestinal safety. The additional key to the marketing success is the purity and simplicity of the message-that is, COX-1 inhibition causes the gastrointestinal side effects of NSAIDs (COX-1 dogma) while COX-2 blocking confers the therapeutic benefits (COX-2 dogma). Adherence to the COX dogmas with development of COX-2 selective agents has undoubtedly benefited many patients, but ironically their scientific basis is now seriously challenged by experimentation.
摘要
选择性环氧化酶2（COX-2）抑制剂在市场上取得的巨大成功，很大程度上是基于其疗效与传统非甾体抗炎药（NSAIDs）相当，同时胃肠道安全性有了极大改善。该药物市场成功的另一个关键因素是信息的简洁明了，即COX-1抑制会导致NSAIDs的胃肠道副作用（COX-1教条），而COX-2阻断则带来治疗益处（COX-2教条）。遵循这些COX教条开发COX-2选择性药物无疑使许多患者受益，但具有讽刺意味的是，它们的科学依据现在正受到实验的严峻挑战。
相似文献
1
NSAIDs: the emperor's new dogma?非甾体抗炎药：皇帝的新教条？
Gut. 2003 Sep;52(9):1376-8. doi: 10.1136/gut.52.9.1376.
2
COX-2-Selective NSAIDs: new and improved?COX-2 选择性非甾体抗炎药：新且有所改进？
JAMA. 2000 Sep 13;284(10):1297-9. doi: 10.1001/jama.284.10.1297.
3
New dogmas or old?新教条还是旧教条？
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
4
Cox-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly.环氧化酶-2抑制剂及其他非甾体抗炎药用于治疗老年人疼痛
Clin Geriatr Med. 2001 Aug;17(3):489-502, vi. doi: 10.1016/s0749-0690(05)70082-3.
5
[Non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors].[非甾体抗炎药与环氧化酶-2特异性抑制剂]
Wien Med Wochenschr. 1999;149(19-20):541-5.
6
Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?环氧化酶-2抑制剂是否能提供与传统非甾体抗炎药类似的益处，同时胃肠道毒性更低？
Ann Intern Med. 2000 Jan 18;132(2):134-43. doi: 10.7326/0003-4819-132-2-200001180-00008.
7
Efficacy of cyclooxygenase-2-specific inhibitors.环氧化酶-2特异性抑制剂的疗效。
Am J Med. 2001 Feb 19;110 Suppl 3A:6S-12S. doi: 10.1016/s0002-9343(00)00681-1.
8
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.塞来昔布与非甾体抗炎药治疗骨关节炎和类风湿关节炎的胃肠道毒性：CLASS研究：一项随机对照试验。塞来昔布长期关节炎安全性研究。
JAMA. 2000 Sep 13;284(10):1247-55. doi: 10.1001/jama.284.10.1247.
9
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors.非甾体抗炎药所致胃肠道损伤与修复的机制：环氧化酶抑制性一氧化氮供体的机遇之窗
Can J Gastroenterol. 2004 Apr;18(4):229-36. doi: 10.1155/2004/890585.
10
Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.基于生物化学的环氧化酶-2（COX-2）抑制剂设计：非甾体抗炎药向强效且高选择性COX-2抑制剂的简便转化。
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30. doi: 10.1073/pnas.97.2.925.
引用本文的文献
1
A Review of Anti-Inflammatory Drug-Induced Gastrointestinal Injury: Focus on Prevention of Small Intestinal Injury.抗炎药物所致胃肠道损伤综述：聚焦小肠损伤的预防
Pharmaceuticals (Basel). 2010 Apr 20;3(4):1187-1201. doi: 10.3390/ph3041187.
2
Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora.非甾体抗炎药所致小肠损伤与肠道菌群关系的最新概念
Clin J Gastroenterol. 2013 Oct;6(5):345-51. doi: 10.1007/s12328-013-0424-8. Epub 2013 Sep 20.
3
The impact of non-steroidal anti-inflammatory drugs on the small intestinal epithelium.非甾体抗炎药对小肠上皮的影响。
J Clin Biochem Nutr. 2014 Jan;54(1):2-6. doi: 10.3164/jcbn.13-84. Epub 2013 Dec 18.
4
[NSAID-colonopathy].[非甾体抗炎药相关性结肠病]
Pathologe. 2006 Feb;27(1):65-72. doi: 10.1007/s00292-005-0810-1.
5
Strictures, diaphragms, erosions or ulcerations of ischemic type in the colon should always prompt consideration of nonsteroidal anti-inflammatory drug-induced lesions.结肠中出现的狭窄、隔膜、缺血型糜烂或溃疡，应始终促使人们考虑非甾体抗炎药引起的病变。
World J Gastroenterol. 2005 Oct 7;11(37):5828-33. doi: 10.3748/wjg.v11.i37.5828.
6
Gastroprotective action of glucocorticoid hormones during NSAID treatment.非甾体抗炎药治疗期间糖皮质激素的胃保护作用。
Inflammopharmacology. 2005;13(1-3):27-43. doi: 10.1163/156856005774423746.
7
Is no NSAID a good NSAID? Approaches to NSAID-associated upper gastrointestinal disease.没有非甾体抗炎药是好的非甾体抗炎药吗？非甾体抗炎药相关性上消化道疾病的处理方法。
Curr Gastroenterol Rep. 2004 Dec;6(6):447-53. doi: 10.1007/s11894-004-0066-6.
8
New dogmas or old?新教条还是旧教条？
Gut. 2003 Sep;52(9):1379-81. doi: 10.1136/gut.52.9.1379.
本文引用的文献
1
Lack of cardioprotective effect of naproxen.萘普生缺乏心脏保护作用。
Arch Intern Med. 2002;162(22):2637; author reply 2638-9. doi: 10.1001/archinte.162.22.2637.
2
Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.罗非昔布、塞来昔布和萘普生对正常盐饮食老年受试者肾功能的比较。
Clin Pharmacol Ther. 2002 Jul;72(1):50-61. doi: 10.1067/mcp.2002.126182.
3
COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.COX - 1和COX - 2、肠道完整性与小鼠非甾体抗炎药肠病的发病机制
Gastroenterology. 2002 Jun;122(7):1913-23. doi: 10.1053/gast.2002.33647.
4
Differential effect of FR122047, a selective cyclo-oxygenase-1 inhibitor, in rat chronic models of arthritis.选择性环氧化酶-1抑制剂FR122047在大鼠慢性关节炎模型中的差异作用。
Br J Pharmacol. 2002 Feb;135(3):782-8. doi: 10.1038/sj.bjp.0704511.
5
Cyclooxygenase-2--10 years later.环氧化酶-2——十年之后
J Pharmacol Exp Ther. 2002 Feb;300(2):367-75. doi: 10.1124/jpet.300.2.367.
6
Inflammatory bowel disease and spondylarthropathy.炎症性肠病和脊柱关节病。
Arthritis Rheum. 2001 Dec;44(12):2728-36. doi: 10.1002/1529-0131(200112)44:12<2728::aid-art459>3.0.co;2-8.
7
Effects of specific inhibition of cyclo-oxygenase-1 and cyclo-oxygenase-2 in the rat stomach with normal mucosa and after acid challenge.环氧化酶 -1 和环氧化酶 -2 的特异性抑制对正常黏膜及酸刺激后大鼠胃的影响。
Br J Pharmacol. 2001 Apr;132(7):1565-73. doi: 10.1038/sj.bjp.0703955.
8
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.罗非昔布与萘普生对类风湿关节炎患者上消化道毒性的比较。VIGOR研究组。
N Engl J Med. 2000 Nov 23;343(21):1520-8, 2 p following 1528. doi: 10.1056/NEJM200011233432103.
9
10
NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.非甾体抗炎药诱导的大鼠胃损伤：同时抑制环氧化酶1和2的必要性。
Gastroenterology. 2000 Sep;119(3):706-14. doi: 10.1053/gast.2000.16510.
Zotero 插件